CAPR Financials Monday, July 14, 2014 12:31:38 PM
Capricor Therapeutics, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 503 1,899 1,355 -
Cost of Revenue - - - -
Gross Profit 503 1,899 1,355 -
Operating Expenses
Research and Development 5,197 2,634 4,137 4,081
Sales, General and Admin. 2,209 1,365 2,117 2,213
Non-Recurring Items - - - -
Other - - - -
Operating Income (6,903) (2,100) (4,899) (6,294)
Income From Continuing Operations
Add'l Income/Expense Items (1,931) 29 14 262
Earnings Before Interest and Tax (8,834) (2,071) (4,885) (6,031)
Interest Expense 58 - - -
Earnings Before Tax (8,892) (2,071) (4,885) (6,031)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (8,892) (2,071) (4,885) (6,031)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (8,892) (2,071) (4,885) (6,031)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (8,892) (2,071) (4,885) (6,031)